NASDAQ:MASI - Masimo Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started $113.52 +1.26 (+1.12 %) (As of 08/16/2018 04:00 PM ET)Previous Close$112.26Today's Range$111.84 - $114.0152-Week Range$80.69 - $114.01Volume385,900 shsAverage Volume540,186 shsMarket Capitalization$5.68 billionP/E Ratio46.36Dividend YieldN/ABeta0.89 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation has a strategic partnership with NU Hospitals. The company was founded in 1989 and is headquartered in Irvine, California. Receive MASI News and Ratings via Email Sign-up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:MASI CUSIP57479510 Webwww.masimo.com Phone949-297-7000 Debt Debt-to-Equity RatioN/A Current Ratio5.05 Quick Ratio4.35 Price-To-Earnings Trailing P/E Ratio46.36 Forward P/E Ratio39.14 P/E Growth2.56 Sales & Book Value Annual Sales$798.11 million Price / Sales7.36 Cash Flow$3.1490 per share Price / Cash36.05 Book Value$13.68 per share Price / Book8.30 Profitability EPS (Most Recent Fiscal Year)$2.45 Net Income$131.61 million Net Margins15.30% Return on Equity21.49% Return on Assets17.18% Miscellaneous Employees1,400 Outstanding Shares51,780,000Market Cap$5.68 billion Masimo (NASDAQ:MASI) Frequently Asked Questions What is Masimo's stock symbol? Masimo trades on the NASDAQ under the ticker symbol "MASI." How were Masimo's earnings last quarter? Masimo Co. (NASDAQ:MASI) released its earnings results on Wednesday, August, 1st. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.71 by $0.02. The medical equipment provider had revenue of $211.62 million for the quarter, compared to the consensus estimate of $207.85 million. Masimo had a return on equity of 21.49% and a net margin of 15.30%. Masimo's quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.83 earnings per share. View Masimo's Earnings History. When is Masimo's next earnings date? Masimo is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Masimo. What guidance has Masimo issued on next quarter's earnings? Masimo updated its FY18 earnings guidance on Wednesday, August, 1st. The company provided EPS guidance of $2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.89. The company issued revenue guidance of $850 million, compared to the consensus revenue estimate of $848.37 million. What price target have analysts set for MASI? 4 analysts have issued 1 year price targets for Masimo's shares. Their forecasts range from $94.00 to $112.00. On average, they anticipate Masimo's share price to reach $100.75 in the next year. This suggests that the stock has a possible downside of 11.2%. View Analyst Price Targets for Masimo. What is the consensus analysts' recommendation for Masimo? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Masimo. Are investors shorting Masimo? Masimo saw a increase in short interest in the month of July. As of July 13th, there was short interest totalling 1,398,421 shares, an increase of 71.7% from the June 29th total of 814,473 shares. Based on an average daily trading volume, of 489,980 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.9% of the company's stock are sold short. View Masimo's Current Options Chain. Who are some of Masimo's key competitors? Some companies that are related to Masimo include SONOVA Hldg AG/ADR (SONVY), Varian Medical Systems (VAR), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), CONMED (CNMD), NxStage Medical (NXTM), AxoGen, Inc Common Stock (AXGN), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), electroCore (ECOR), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Vision Sciences (CGNT) and Helius Medical Technologies (HSDT). Who are Masimo's key executives? Masimo's management team includes the folowing people: Mr. Micah Young, Exec. VP of Fin. & CFO (Age 39)Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 53)Mr. Anand Sampath, Chief Operating Officer (Age 52)Mr. David J. Van Ramshorst, Chief Accounting Officer & Sr. VP of Fin. (Age 57)Mr. Yongsam Lee, Exec. VP & Chief Information Officer (Age 53) Has Masimo been receiving favorable news coverage? News headlines about MASI stock have trended positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Masimo earned a news and rumor sentiment score of 0.35 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 51.68 out of 100, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View Recent Headlines for Masimo. Who are Masimo's major shareholders? Masimo's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.04%), FMR LLC (3.52%), Schroder Investment Management Group (1.54%), Point72 Asset Management L.P. (1.43%), Bank of New York Mellon Corp (1.21%) and Renaissance Technologies LLC (1.07%). Company insiders that own Masimo stock include Anand Sampath, Joe E Kiani, Jon Coleman, Paul Jansen, Raad Mark De, Ramshorst David J Van, Rick Fishel, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee. View Institutional Ownership Trends for Masimo. Which institutional investors are selling Masimo stock? MASI stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., Voya Investment Management LLC, American Century Companies Inc., Acadian Asset Management LLC, Morgan Stanley, Canada Pension Plan Investment Board and Bank of New York Mellon Corp. Company insiders that have sold Masimo company stock in the last year include Joe E Kiani, Jon Coleman, Ramshorst David J Van, Sanford Fitch, Steven Barker and Yongsam Lee. View Insider Buying and Selling for Masimo. Which institutional investors are buying Masimo stock? MASI stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Schroder Investment Management Group, Caisse DE Depot ET Placement DU Quebec, Marshall Wace LLP, First Quadrant L P CA, Frontier Capital Management Co. LLC, Bank of Nova Scotia and Paloma Partners Management Co. View Insider Buying and Selling for Masimo. How do I buy shares of Masimo? Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Masimo's stock price today? One share of MASI stock can currently be purchased for approximately $113.52. How big of a company is Masimo? Masimo has a market capitalization of $5.68 billion and generates $798.11 million in revenue each year. The medical equipment provider earns $131.61 million in net income (profit) each year or $2.45 on an earnings per share basis. Masimo employs 1,400 workers across the globe. How can I contact Masimo? Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected] MarketBeat Community Rating for Masimo (NASDAQ MASI)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 283 (Vote Outperform)Underperform Votes: 276 (Vote Underperform)Total Votes: 559MarketBeat's community ratings are surveys of what our community members think about Masimo and other stocks. Vote "Outperform" if you believe MASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MASI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/16/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?